KyungDong Pharm home
Prescription Medicines

Amoctin Duo Syrup

Product Category
broad-spectrum antibiotics
Active Ingredients
Amoxicillin hydrate diluted potassium clavulanate
Appearance
A white-white powder with a peculiar odor that is dissolved in syrup when used.
Reimbursement Code
648103271
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
Of 100g (908.15mL)
- Active ingredients:
Amoxicillin hydrate (KP) ---------------- 36.3143g (titer)
Dilute Potassium Clavulanate (EP) -------------- 5.1878 g (Titer (as clavulanic acid))
- Additives (animal-derived ingredients): Lactose (cow, milk) in strawberry-flavored cotton
- Other additives: Strawberry flavored cotton, citric acid, sodium citrate hydrate, aspartame, silicon dioxide, xanthan gum, colloidal silicon dioxide, povidone, enzyme-treated stevia, D-mannitol

2. Effectiveness
○ Effective bacterial species
*Staphylococcus aureus, *Staphylococcus epidermidis, Streptococcus pyogenes (group A-beta-hemolytic), Streptococcus pneumoniae, Streptococcus viridans, Enterococcus phycalis, Corynebacterium, Anthrax, Listeria monocytogenes, Clostridium, Peptococcus, Peptococcus, *Escherichia coli, *Proteus Mirabilis, *Proteus vulgaris, *Klebsiella, *Salmonella, *Shigella, Bordetella whooping cough, *Yersinia enterocolitica, Brucella, Neisseria meningitidis, *Gonococci, *Moraxella catarrhalis, *Haemophilus influenzae, animal pasteurellosis pathogens, plant campylobacter, Bacillus cholera, *Bacteroides (Bacteroides fragilis) included)
(*: Includes beta-lactamase producing strains resistant to ampicillin and amoxicillin)

○ Indications
- Acute and chronic bronchitis, lobar and bronchial pneumonia, empyema, lung abscess, tonsillitis, sinusitis, otitis media
- Cystitis, urethritis, pyelonephritis
- Pelvic infection, gonorrhea
- Boils and abscesses, cellulitis, wound infections
- Osteomyelitis
- Dental infection

3. Dosage and dosage
○ For mild to moderate infections such as upper respiratory tract infections such as recurrent tonsillitis, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections, amoxicillin/clavulanate potassium is usually taken at 25 mg/3.6 mg/kg of body weight per day in two divided doses.
○ In case of severe infections such as upper respiratory tract infections such as otitis media and sinusitis, lower respiratory tract infections such as bronchopneumonia, and urinary tract infections, amoxicillin/clavulanate potassium is usually taken at 45 mg/6.4 mg per kg of body weight per day in two divided doses.
․ 7:1 syrup is not suitable for use under 2 months.
․ For pediatric patients with renal failure, 7:1 syrup is not suitable.
Administer at the beginning of a meal to minimize potential gastrointestinal intolerance. Absorption of amoxicillin-clavulanic acid is optimized when administered early in the meal.

<How to prepare this medicine>
Pour water up to 2/3 of the marked line and mix well, then fill with water up to the marked line and shake well before use.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity (e.g., anaphylaxis, cutaneous muco-ocular syndrome (Stevens-Johnson syndrome), shock included) to the ingredients of this drug or beta-lactams (penicillin, Cefem) (there is a risk of cross-hypersensitivity to beta-lactams)
2) Patients with concomitant viral diseases, especially infectious mononucleosis and lymphocytic leukemia (the risk of rash may increase)
3) Patients with a history of jaundice or liver dysfunction caused by this drug or penicillin (may recur)

2. Administer with caution to the following patients.
1) Patients with liver dysfunction (liver dysfunction may worsen)
2) Patients with moderate or severe renal impairment (use at intervals between administrations as blood concentration persists)
3) Patients whose parents or siblings are prone to allergic symptoms such as bronchial asthma, rashes, and hives
4) Patients with poor oral intake, parenteral nutrition patients, the elderly, and patients in poor general condition (symptoms of vitamin K deficiency may appear)
5) Patients with digestive system disease accompanied by vomiting and diarrhea (sufficient absorption of the drug cannot be guaranteed)

3. Adverse reactions
1) Digestive system: Diarrhea, pseudomembranous colitis, indigestion, stomatitis, rarely gastritis, glossitis, black hair tongue, sometimes nausea, vomiting, loss of appetite, abdominal pain, abdominal distension, constipation, colonic pain, gastric acidosis, loose stool, dry mouth, etc. may occur. In addition, acute pancreatitis occurs with unknown frequency, and candidiasis and antibiotic-induced colitis (including pseudomembranous colitis and hemorrhagic colitis) are rarely reported. Severe colitis accompanied by bloody stool may occur, so observe thoroughly, and if abdominal pain or frequent diarrhea occurs, immediately stop administration and take appropriate measures. Although rare, nausea is the most common symptom when taking high doses. Gastrointestinal adverse reactions that occur due to oral administration can be alleviated by taking this drug at the beginning of a meal.
As with other antibiotics, the rate of adverse gastrointestinal reactions may increase in infants under 2 years of age. However, in clinical trials, only 4% of infants under 2 years of age discontinued treatment.
2) Liver: Occasionally, elevations of AST, ALT, ALP, LDH, and serum bilirubin may occur, and in rare cases, hepatitis and cholestatic jaundice may occur. These symptoms appear more commonly when using this drug than with other penicillin products, and are reported to occur more frequently in adults, the elderly (especially those over 60 years of age), and men. Signs and symptoms of adverse reactions may appear during treatment, but in many cases they are reported late, up to 6 weeks after discontinuation of treatment. Adverse reactions to the liver are generally reversible, but extremely rare cases of death have been reported. These deaths were generally related to serious chronic diseases or concomitant medications. Adverse reactions to the liver are mainly reported in men and the elderly, and these adverse reactions increase further with long-term administration for more than 14 days. Histological observation by liver biopsy showed cholestatic, hepatocellular, or mixed cholestatic and hepatocellular changes. In particular, it has been rarely reported in children. The administration period must be appropriately reviewed depending on the indication and should not exceed 14 days without review.
3) Hypersensitivity reaction: Rare cases of itching, erythema multiforme exudative, ocular mucocutaneous syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), bullous exfoliative dermatitis, and acute generalized exudative pustulosis have been reported. These skin reactions can be controlled with antihistamines or, if necessary, systemic administration of corticosteroids. If these rash symptoms appear, stop taking the medication and follow the doctor's instructions. Drug reaction with Eosinophilla and Systemic Symptoms (DRESS) has been reported. As with other beta-lactam antibiotics, rare cases include angioedema, anaphylactic serum sickness syndrome [seropathogenic type III hypersensitivity reaction (immune complex disease) characterized by fever, rash (especially perioral skin rash, urticaria, and marginal rash), arthralgia, edema, and lymphadenopathy] and hypersensitivity vasculitis, acute systemic exanthematous pustulosis, dyspnea with bronchospasm, laryngeal edema, Symptoms of a drop in blood pressure leading to anaphylactic shock have been reported.
4) Blood system: Like other beta-lactam antibiotics, rare cases of reversible leukocyte reduction (including neutrophil reduction and granulocyte deficiency), reversible thrombocytopenia and hemolytic anemia, anemia, thrombocytopenic purpura, increased eosinophils, leukemia, agranulocytosis, decreased lymphocytes, rare but mild increased platelets, and bone marrow suppression have been reported. Additionally, prolonged bleeding time and prothrombin time have been rarely reported.
5) Urinary system: Vaginal itching, soreness, increased secretions, etc. may occur, including mucosal candidiasis.
6) Central nervous system: In extremely rare cases, adverse reactions to the central nervous system have been confirmed. Adverse reactions include nervousness, anxiety, behavioral changes, confusion, drowsiness, insomnia, reversible hyperactivity, dizziness, and rarely headache and convulsions. Convulsive symptoms may occur in patients with impaired renal function or in patients receiving high doses. Aseptic meningitis accompanied by neck stiffness, fever, headache, nausea/vomiting, or clouding of consciousness may occur. If such symptoms appear, discontinue administration and take appropriate measures.
7) Kidney: In rare cases, severe renal disorders such as acute renal failure, interstitial nephritis, and related hematuria may occur. Therefore, observe thoroughly, including regular examinations, and if abnormalities are recognized, discontinue administration and take appropriate measures.
8) Mycosis: In rare cases, stomatitis and candidiasis may occur. If these symptoms appear, take appropriate measures, such as discontinuing administration.
9) Vitamin deficiency: In rare cases, symptoms of vitamin K deficiency (hypoprothrombinemia, bleeding tendency, etc.) and vitamin B deficiency symptoms (glossitis, stomatitis, loss of appetite, neuritis, etc.) may appear.
10) Others: Tooth staining has been very rarely reported in children and, rarely, in adults. However, since it is usually removed by brushing your teeth, you can prevent tooth discoloration if you practice thorough oral hygiene (syrup products only). Linear IgA disease may occur with unknown frequency, and in rare cases, taste abnormalities and malaise have been reported.
11) As a result of analysis and evaluation of clue information based on domestic post-marketing adverse event reporting data (1989 ~ 2015), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
· Skin and subcutaneous tissue system: dermatitis
· Abnormalities in the entire body and administration site: oral edema

4. General precautions
1) When using this drug, in order to prevent the development of resistant bacteria, it is advisable to confirm sensitivity and administer only the minimum period necessary for treatment.
2) Serious, sometimes fatal hypersensitivity reactions (including anaphylactoid reactions and severe skin reactions) and angioedema may occur in patients receiving penicillin. This reaction is more likely to occur in patients with a history of penicillin hypersensitivity or sensitivity to multiple allergens, and occurs more frequently with parenteral therapy, but also occurs with oral therapy. Hypersensitivity reactions can progress to Conis syndrome, a serious allergic reaction that can lead to myocardial infarction.
3) Since anaphylactic shock may occur very rarely, it must be closely monitored and treated to maintain a stable condition. After administration, keep the patient in a stable condition and conduct sufficient observation. If severe anaphylaxis occurs, provide rapid first aid such as epinephrine. Treatments such as intubation, intravenous administration of oxygen and corticosteroids, and securing the airway are performed according to the doctor's instructions.
4) Pseudomembranous colitis has been reported to range from mild to life-threatening in relation to the use of antibiotics. Therefore, pseudomembranous colitis should be considered in patients who develop diarrhea during or after antibiotic use. If prolonged or severe diarrhea occurs, or if the patient develops abdominal cramps, use of this drug should be discontinued immediately and the patient should be further investigated. The use of antibiotics can cause changes in the intestinal flora, causing overgrowth of Clostridium. Studies have shown that toxins produced by Clostridium difficile are the main cause of antibiotic-related colitis. Once a diagnosis of pseudomembranous colitis is made, treatment should be initiated. Mild pseudomembranous colitis can be reversed by discontinuing medication. In moderate or severe cases, treatment includes fluid, electrolyte, and protein supplementation and treatment with antibiotics that are clinically effective against Clostridium difficile.
5) During long-term administration, excessive growth of non-susceptible bacteria may sometimes occur, so observe thoroughly when administering for more than 14 days.
6) Changes in liver function tests have been confirmed in some patients receiving this drug. The clinical significance is uncertain, but it should be used with caution in patients with signs of liver dysfunction. Severe but usually reversible cholestatic jaundice has been rarely reported. Symptoms and signs may not appear outwardly until 6 weeks after discontinuation of treatment.
7) Since most of this drug is excreted through the kidneys, in patients with moderate to severe renal impairment, the amount of this drug used should be adjusted according to the dosage section in the dosage instructions.
8) Since erythematous rash is related to infectious mononucleosis caused by the use of amoxicillin, use of this drug should be avoided if infectious mononucleosis is a concern.
9) If symptoms such as hives, skin rash, or serum sickness appear, stop taking the drug and take appropriate measures according to the doctor's instructions.
10) Although this drug has relatively low toxicity among penicillin antibiotics, regular observation of renal function, liver function, hematopoietic function, etc. is required for long-term administration.
11) Before starting treatment with this drug, it is necessary to ask about the history of previous hypersensitivity to penicillin, cephalosporin, or other allergens.
12) Shake well before use.
13) After preparation, store in the refrigerator and use within 7 days.
14) Crystalluria (including acute renal injury) was very rarely observed in patients with reduced urine output, mainly in relation to parenteral therapy. When administering high doses, appropriate fluid intake and urine output must be maintained to prevent amoxicillin crystalluria.
15) Drug-induced enterocolitis syndrome (DIES) was mainly reported in children receiving amoxicillin. DIES is an allergic reaction whose main symptom is delayed vomiting (1-4 hours after taking, administering, or using medicine) without skin or respiratory allergic symptoms. Other symptoms may include abdominal pain, diarrhea, low blood pressure, and leukocytosis with neutrophilia, and severe cases have been reported (including one that progressed to shock).

5. Interaction
1) Concurrent administration with probenecid is not recommended. This reduces the renal tubular excretion of amoxicillin, which may cause the blood concentration of amoxicillin to continue to rise, and clavulanic acid is not involved.
2) When allopurinol and ampicillin are administered together, there is a higher possibility of allergic skin reactions (rashes) occurring compared to patients who receive ampicillin alone, but it is not clear whether this is caused by allopurinol or hyperuricemia.
3) Do not administer in combination with disulfiram.
4) Prolongation of bleeding time and prothrombin time has been reported in some patients receiving this drug, so administer with caution to patients on anticoagulant therapy.
5) Patients should be cautioned as it may affect the intestinal flora and reduce the effectiveness of oral contraceptives.
6) When acetylsalicylic acid, phenylbutazone, and large amounts of anti-inflammatory drugs are administered simultaneously with penicillin, blood concentrations increase.
7) Antagonism occurs when administered in combination with oral chemotherapy antibiotics, including tetracyclines, macrolides, sulfonamides, and chloramphenicol.
8) Simultaneous administration with sulfasalazine reduces the plasma concentration of sulfasalazine.
9) Amoxicillin reduces the renal clearance of methotrexate.
10) Changes in INR (international normalized ratio): An increase in anticoagulant activity has been reported in patients who received antibiotics, including this drug, simultaneously with anticoagulants. Infectious diseases (and accompanying inflammatory processes), age and general condition of the patient are risk factors. Although the interaction between this drug and warfarin has not been revealed through clinical trials, INR monitoring should be performed and, if necessary, the dose of oral anticoagulant should be adjusted appropriately. Some types of antibiotics, especially fluoroquinolones, macrolides, cyclins, cotrimoxazole and some cephalosporins, are more severe.
11) The use of antibiotics affects the intestinal flora, which may increase the absorption of cardiac glycosides (digoxin, etc.) in some patients.
12) A case was reported in which the trough blood concentration of mycophenolate mofetil (pre-dose, trough) of mycophenolate mofetil decreased to approximately 50% for several days immediately after taking oral amoxicillin/clavulanate potassium together in a patient receiving mycophenolate mofetil. This phenomenon decreased with continued administration and disappeared after discontinuation of administration. Since changes in trough blood concentration cannot be considered to accurately reflect changes in mycophenolic acid exposure, the clinical significance of this phenomenon is not clear.

6. Administration to pregnant and lactating women
1) Although it did not cause teratogenic effects in animal tests, the safety of administration during pregnancy has not been established. Therefore, it should be administered to pregnant women or women who may be pregnant only when the benefits of treatment are judged to outweigh the risks. In particular, it should not be administered during the first three months of pregnancy.
2) During breastfeeding, trace amounts of penicillin (including ampicillin) may pass into breast milk.
3) Administration to a nursing mother may cause risk of diarrhea, fungal growth of the mucous membrane, hypersensitivity reaction (skin rash, etc.) to the infant, so if any adverse reaction occurs, discontinue administration.

7. Administration to children
Safety in premature infants and neonates (less than 2 months of age) has not been established.

8. Administration to elderly people
For elderly patients, administer carefully while observing the patient's condition, paying attention to the following points and paying attention to the dosage and administration interval.
1) Because physiological function is often reduced, adverse reactions are likely to occur.
2) Bleeding tendencies may occur due to vitamin K deficiency.

9. Effect on clinical test values
1) This drug is excreted in large quantities in the urine, and high concentrations of urinary ampicillin may result in false positive results in urine glucose tests using Benedict's reagent, Felling's reagent, or Clinitest, so be careful. Therefore, it is not recommended to perform these tests while administering this drug to patients. The Testape test is not affected by this drug.
2) When ampicillin was administered to pregnant women, the concentration of total conjugated estriol, estriol glucuronide, conjugated estrone, and estradiol in plasma was observed to temporarily decrease. These results were also observed when administering amoxicillin and this drug.
3) It may also affect the urobilinogen test.
4) Clavulanic acid tends to be absorbed onto the surface of red blood cell membranes. If antibodies to the drug are present, a positive Coombs test result may be indicated.
5) Be careful when administering high concentrations of amoxicillin because the following tendencies occur. : Color reaction interferes with determining the total protein ratio of serum.

10. Treatment in case of overdose
1) Symptoms
(1) Problems due to overdose rarely occur, but if they do occur, digestive symptoms (stomach pain, abdominal pain, diarrhea, vomiting, etc.), abnormal body fluid and electrolyte balance, and in a few cases, rash, hyperactivity, and drowsiness may appear.
(2) In rare cases of amoxicillin overdose, interstitial nephritis due to oliguria and renal failure may be reported. Symptoms of renal failure may be reversible when treatment with this drug is stopped. Due to the decreased renal clearance of amoxicillin and clavulanate potassium, patients with renal failure maintain high blood levels.
(3) When penicillin is administered in high doses, epileptic cerebral convulsions may occur. Although it is not a symptom of poisoning in patients receiving penicillin, a phenomenon that can occur frequently is anaphylaxis. Although rare, it can be acute and fatal. Typically, it may appear within 30 minutes immediately after administration. All possible measures should be taken immediately to normalize blood circulation.
(4) Other allergic reactions, such as skin reactions, bleeding, and pancellular reduction, may also occur.
2) Treatment: In such cases, stop administration immediately and treat while paying attention to the water and electrolyte balance according to the symptoms. This drug can be removed by hemodialysis.
If the overdose occurred not long ago and is not subject to contraindications, vomiting or other methods to remove stomach contents can also be used.
In case of convulsions due to overdose, soothe with diazepam.

11. Storage and handling precautions
Store in a dry place below 25 ℃, and after suspension, store under refrigerated conditions (2 to 8 ℃) for 7 days.

12. Others
There is one study that suggests that prophylactic administration of this drug to women with premature rupture of fetal membranes is associated with an increased risk of developing necrotizing enterocolitis in their newborns. As with other medications, use of this medication should be avoided unless deemed necessary by your doctor.

5. How to save
Airtight container, stored in dry place below 25℃

6. Packaging unit
50mL/bottle, 250mL/bottle

7. Period of use
24 months from date of manufacture

Product Updates

Total 5items

No.Product NameDetailsDate of ChangeDownload
5Amoctin Duo SyrupPrecautions for use2024.06.26PDF0190_201307134_Amoktin Duo Syrup_Precautions for Use (Change).pdf
4Amoctin Duo SyrupAmoctin Duo Syrup (Precautions for use)2017.12.01PDFPrecautions for using Amoctin Duo Syrup.pdf
3Amoctin Duo SyrupAmoctin Duo Syrup (effectiveness, dosage, usage instructions...2017.08.16PDF2016 Pharmaceutical Literature Re-evaluation (Amoktin Duo Syrup)_Ogi Correction.
2Amoctin Duo SyrupAmoctin Duo Syrup (Precautions for use)2017.04.21HWP121_Amoktin Duo Syrup.hwp
1Amoctin Duo SyrupAmoctin Duo Syrup (Precautions for use)2015.06.02HWPAmoctin Duo Syrup approval change order 150602.hwp